Search Result

Results for "

SGLT

" in MCE Product Catalog:

By Targets:	SGLT (43) Cytochrome P450 (1) Endogenous Metabolite (1) GLUT (1) HIV (1) HSV (1) Na+/K+ ATPase (1) Reactive Oxygen Species (1)
By Research Areas:	Cancer (7) Endocrinology (1) Infection (2) Inflammation/Immunology (1) Metabolic Disease (40) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: SGLT

Cat. No.	Product Name	Target	Research Areas

HY-138944

SGLT1/2-IN-1
SGLT Metabolic Disease

SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .
HY-145357

SGLT1/2-IN-2
SGLT Metabolic Disease

SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC₅₀ = 96 nM for SGLT1 and IC₅₀ = 1.3 nM for SGLT2).

SGLT1/2-IN-1	SGLT	Metabolic Disease
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .

SGLT1/2-IN-2	SGLT	Metabolic Disease
SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC₅₀ = 96 nM for SGLT1 and IC₅₀ = 1.3 nM for SGLT2).

HY-112807

SGLT inhibitor-1	SGLT	Metabolic Disease
SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC₅₀s of 43 nM and 9 nM, respectively.

HY-N4100

Trilobatin	HIV SGLT	Infection
Trilobatin, a natural sweetener derived from Lithocarpus polystachyus Rehd, Trilobatin is an HIV-1 entry inhibitor targeting the HIV-1 Gp41 envelope. Neuroprotective effects. Trilobatin is also a SGLT1/2 inhibitor that selectively induces the proliferation of human hepatoblastoma cells.

HY-14894

Ipragliflozin ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.

HY-15409

Empagliflozin
BI 10773
SGLT Metabolic Disease

Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2.

Empagliflozin BI 10773	SGLT	Metabolic Disease
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2.

HY-15409S

Empagliflozin-d4 BI 10773-d₄	SGLT	Metabolic Disease
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

HY-109092

Licogliflozin
LIK066
SGLT Metabolic Disease Inflammation/Immunology

Licogliflozin is a sodium glucose cotransporter (SGLT1 and SGLT2) inhibitor.

Licogliflozin LIK066	SGLT	Metabolic Disease Inflammation/Immunology
Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2*) inhibitor.

HY-14894A

Ipragliflozin (L-Proline)	SGLT	Metabolic Disease
Ipragliflozin (L-Proline) is a highly potent and selective *SGLT2* inhibitor with an IC₅₀ of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

HY-123797

KGA-2727	SGLT	Metabolic Disease
KGA-2727 is a first selective, high-affinity and orally active *SGLT1* inhibitor with K_is of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for *SGLT1*) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy.

HY-15516

Sotagliflozin
LX-4211; LP-802034
SGLT Metabolic Disease

Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

Sotagliflozin LX-4211; LP-802034	SGLT	Metabolic Disease
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-14902

Tofogliflozin CSG452	SGLT	Metabolic Disease
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research.

HY-106158

T-1095	SGLT	Metabolic Disease
T-1095 is a selective and orally active Na⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research.

HY-13414

Remogliflozin Remogliflozin A	SGLT	Metabolic Disease
Remogliflozin is a potent and selective inhibitor of *SGLT2* (sodium-glucose cotransporter 2) with K_is of 12.4 and 26 nM for human and rat SGLT2, respectively.

HY-101122

LX2761	SGLT	Metabolic Disease
LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and *SGLT2* in vitro with IC₅₀s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract.

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

HY-17638

Mizagliflozin DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective *SGLT1* inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic drug that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation.

HY-13413

Tofogliflozin (hydrate) CSG-452 hydrate	SGLT Reactive Oxygen Species	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse *SGLT2. Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS)* generation in tubular cells.

HY-117010

Kushenol K	Cytochrome P450 HSV SGLT	Infection Metabolic Disease
Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a K_i value of 1.35 μM. Kushenol K shows weak antiviral activity against HSV-2 (EC₅₀ of 147 μM). Kushenol K also inhibits the activity of *SGLT1* and *SGLT2*.

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM).

HY-15461

Ertugliflozin PF-04971729	SGLT	Metabolic Disease
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.

HY-10449

Luseogliflozin TS 071	SGLT	Metabolic Disease
Luseogliflozin (TS 071) is a potent, selective, orally active *sodium-dependent glucose cotransporter (SGLT) 2* inhibitor, with an IC₅₀ of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM). Luseogliflozin has the protential for treating type 2 diabetes.

HY-15461A

Ertugliflozin L-pyroglutamic acid PF-04971729 L-pyroglutamic acid	SGLT	Metabolic Disease
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.

HY-109018

Velagliflozin
SGLT Metabolic Disease

Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
HY-10451S

Canagliflozin-d4
JNJ 28431754-d₄
SGLT Cancer Metabolic Disease

Canagliflozin-d₄ is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor[1].
HY-10450S

Dapagliflozin-d5
BMS-512148-d₅
SGLT Cancer Metabolic Disease

Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor[1].
HY-101782

HSK0935
SGLT Metabolic Disease

HSK0935 is a potent, highly selective and orally available SGLT2 inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities.

Velagliflozin	SGLT	Metabolic Disease
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

Canagliflozin-d4 JNJ 28431754-d₄	SGLT	Cancer Metabolic Disease
Canagliflozin-d₄ is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor[1].

Dapagliflozin-d5 BMS-512148-d₅	SGLT	Cancer Metabolic Disease
Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor[1].

HSK0935	SGLT	Metabolic Disease
HSK0935 is a potent, highly selective and orally available *SGLT2* inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities.

HY-N0143

Phlorizin Floridzin; NSC 2833	SGLT Na+/K+ ATPase	Metabolic Disease
Phlorizin is a non-selective *SGLT* inhibitor with K_is of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na⁺/K⁺-ATPase inhibitor.

HY-N0142

Phloretin NSC 407292; RJC 02792	SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.

HY-I0383

Canagliflozin hemihydrate JNJ 28431754 hemihydrate	SGLT	Cancer Metabolic Disease
Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

HY-10451

Canagliflozin JNJ 28431754	SGLT	Metabolic Disease Cancer
Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

HY-109018A

Velagliflozin (proline)	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

HY-12608

TA-1887 JNJ-39933673	SGLT	Metabolic Disease
TA-1887 (JNJ-39933673) is a highly potent, selective and orally active *SGLT2* inhibitor (IC₅₀: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes.

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active *sodium-glucose cotransporter (SGLT) 2* inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes.

HY-109018B

Velagliflozin proline hydrate	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

HY-10451S2

Canagliflozin-d6 JNJ 28431754-d₆	SGLT
Canagliflozin-d₆ is the deuterium labeled Canagliflozin[1]. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[2].

HY-114308

SGL5213	SGLT	Metabolic Disease
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC₅₀ values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment.

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).

HY-10450

Dapagliflozin BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.

HY-14945

Remogliflozin etabonate GSK189075	SGLT	Metabolic Disease
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a prodrug based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models.

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Cancer Metabolic Disease
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of drug used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury.

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	634 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 634 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

634 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 634 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-P3631

SALMF amide 2	Peptides	Neurological Disease
SALMF amide 2, a neuropeptide S2 from the starfish Asterias rubens, is involved in the regulation of eversion of the cardiac stomach in starfish.

Cat. No.	Product Name	Target	Category